To evaluate the efficacy of surufatinib combined with camrelizumab, nab-paclitaxel, and gemcitabine versus nab-paclitaxel plus gemcitabine as the first-line treatment in metastatic pancreatic cancer
Fully understand and voluntarily sign an informed consent form, willing and able to follow the study process;
Age range is 18-75 years old (inclusive);
Pancreatic cancer confirmed by histology or cytology;
Stage IV metastasis Pancreatic cancer patients;
Use of systematic non-specific immunomodulatory therapy within 2weeks prior to the first dose；
Presence of other malignancies in the past 5 years;
Received major surgical surgery within 4 weeks before the first dose;
Received palliative radiotherapy within 1 week before the first dose; received radical radiotherapy within 4 weeks before the first dose;